Pulmonary Embolism: Diagnosis, Risk Stratification, and Anticoagulation

Pulmonary embolism (PE) is the obstruction of one or more pulmonary arteries by thromboembolic material, most commonly originating from deep vein thrombosis (DVT) in the lower extremities. PE represents the third most common acute cardiovascular condition after myocardial infarction and stroke.

[KEY_CONCEPT] PE and DVT are manifestations of the same disease process called venous thromboembolism (VTE), with PE occurring in approximately 30% of patients with untreated proximal DVT.

Epidemiology

• Incidence: 60-70 cases per 100,000 population annually
• Mortality: Case fatality rate of 10-30% if untreated; <2% with appropriate treatment
• Age distribution: Incidence doubles with each decade after age 40
• Gender: Slight female predominance due to pregnancy and oral contraceptive use

Pathophysiology

PE develops through Virchow's triad mechanism:

• Venous stasis: Immobilization, heart failure, varicose veins
• Hypercoagulability: Malignancy, pregnancy, inherited thrombophilias
• Endothelial injury: Surgery, trauma, central venous catheters

[CLINICAL_PEARL] Most clinically significant PEs originate from proximal lower extremity DVTs (iliac, femoral, or popliteal veins), while calf vein thrombi rarely cause significant PE unless they propagate proximally.

Classification by Severity

• Massive PE: Hemodynamic instability (systolic BP <90 mmHg or shock)
• Submassive PE: Hemodynamically stable with RV dysfunction
• Low-risk PE: Hemodynamically stable without RV dysfunction

Clinical Manifestations

[HIGH_YIELD] PE presentation is highly variable and nonspecific. The classic triad of dyspnea, chest pain, and hemoptysis occurs in <20% of patients.

Common Symptoms (frequency)

• Dyspnea: 80-85% (most common)
• Chest pain: 60-70% (pleuritic or substernal)
• Cough: 40-50%
• Leg pain/swelling: 30-40%
• Hemoptysis: 15-20%
• Syncope: 10-15% (suggests massive PE)

Physical Findings

• Tachypnea (>20/min): Most common sign (85%)
• Tachycardia (>100 bpm): 60-70%
• Hypoxemia: 60-80%
• DVT signs: 30-40%
• S₁Q₃T₃ pattern: Classic but rare (20%)

Risk Factor Assessment

[CLINICAL_PEARL] Unprovoked PE (no identifiable risk factors) has a higher recurrence risk and may warrant extended anticoagulation or malignancy screening.

Clinical Prediction Rules

Wells Score for PE

Clinical signs of DVT: 3 points PE most likely diagnosis: 3 points Heart rate >100 bpm: 1.5 points Immobilization ≥3 days or surgery ≤4 weeks: 1.5 points Previous DVT/PE: 1.5 points Hemoptysis: 1 point Malignancy: 1 point

Interpretation: ≤4 points: PE unlikely (prevalence ~10%)

4 points: PE likely (prevalence ~40%)

[KEY_CONCEPT] Clinical prediction rules should always be combined with D-dimer testing and/or imaging studies for diagnostic accuracy.

Diagnostic Algorithm

Suspected PE ↓ Clinical Assessment (Wells Score) ↓ PE Unlikely (Wells ≤4) PE Likely (Wells >4) ↓ ↓ D-dimer CTPA or V/Q Scan ↓ ↓ Normal: PE excluded Positive: PE confirmed Elevated: Imaging Negative: Consider alternative

Laboratory Studies

D-dimer Testing

[HIGH_YIELD] D-dimer has high sensitivity (>95%) but low specificity (~40%) for VTE

• Normal D-dimer + low clinical probability effectively rules out PE
• Elevated D-dimer requires imaging confirmation
• Age-adjusted cutoff: (Age × 10 μg/L) for patients >50 years

Additional Laboratory Tests

• Arterial blood gas: May show hypoxemia, hypocapnia, elevated A-a gradient
• Troponin: Elevated in 30-50% of PE cases (indicates RV strain)
• BNP/NT-proBNP: Elevated with RV dysfunction

Imaging Studies

CT Pulmonary Angiogram (CTPA)

[KEY_CONCEPT] CTPA is the gold standard imaging study for PE diagnosis

• Indications: PE likely or PE unlikely with positive D-dimer
• Contraindications: Severe renal insufficiency, contrast allergy
• Advantages: Widely available, rapid, can identify alternative diagnoses

Ventilation-Perfusion (V/Q) Scan

• Indications: CTPA contraindicated, pregnancy, young patients
• Interpretation: Normal (excludes PE), high probability (confirms PE), intermediate/low probability (requires further testing)

[CLINICAL_PEARL] In pregnancy, V/Q scanning is preferred over CTPA due to lower fetal radiation exposure, unless chest X-ray is abnormal.

Diagnostic Criteria Checklist

PE Diagnosis Confirmed by:

• High-probability V/Q scan
• CTPA showing intraluminal filling defect
• Positive lower extremity ultrasound in clinically suspected PE
• Positive pulmonary angiogram (rarely performed)

PE Diagnosis Excluded by:

• Normal D-dimer + low clinical probability
• Normal CTPA in adequate study
• Normal V/Q scan
• Negative serial lower extremity ultrasounds over 2 weeks

Prognostic Assessment

Risk stratification is crucial for determining treatment intensity and monitoring requirements. [HIGH_YIELD] Hemodynamic stability is the primary determinant of PE severity.

PE Severity Classification

Right Ventricular Assessment

Echocardiographic Signs of RV Dysfunction

• RV dilation: RV:LV ratio >0.9 (apical 4-chamber view)
• RV hypokinesis: Reduced RV free wall motion
• Pulmonary hypertension: TR velocity >2.8 m/s (PASP >35 mmHg)
• McConnell's sign: RV free wall hypokinesis with preserved apical motion

CT Signs of RV Dysfunction

• RV:LV diameter ratio >0.9 on axial images
• Interventricular septal shift toward LV
• Reflux of contrast into inferior vena cava

[CLINICAL_PEARL] McConnell's sign on echocardiography is highly specific (90%) for acute PE when present.

Biomarkers for Risk Stratification

Cardiac Biomarkers

• Troponin elevation: Indicates myocardial injury from RV strain
• BNP/NT-proBNP: Correlates with RV dysfunction severity
• Combined use: Improves prognostic accuracy

Pulmonary Embolism Severity Index (PESI)

PESI Score Calculation: Age (years): ___ Male sex: +10 Cancer: +30 Heart failure: +10 Chronic lung disease: +10 Pulse ≥110 bpm: +20 Systolic BP <100 mmHg: +30 Respiratory rate ≥30/min: +20 Temperature <36°C: +20 Altured mental status: +60 Arterial oxygen saturation <90%: +20

Risk Classes: Class I (≤65): Very low risk (0-1.6% mortality) Class II (66-85): Low risk (1.7-3.5% mortality) Class III (86-105): Intermediate risk (3.2-7.1% mortality) Class IV (106-125): High risk (4.0-11.4% mortality) Class V (>125): Very high risk (10.0-24.5% mortality)

[KEY_CONCEPT] PESI Classes I-II identify patients suitable for outpatient treatment or early discharge, while Classes IV-V require intensive monitoring.

Long-term Prognosis

Recurrence Risk Factors

• Unprovoked PE: 10% annual recurrence risk
• Provoked PE: 1-3% annual recurrence risk after stopping anticoagulation
• Active malignancy: Highest recurrence risk (15-20% annually)

Chronic Complications

• Chronic thromboembolic pulmonary hypertension (CTEPH): 2-4% of PE survivors
• Post-PE syndrome: Persistent dyspnea and exercise limitation in 50% of patients

[CLINICAL_PEARL] Patients with persistent dyspnea 6 months after PE should be evaluated for CTEPH with echocardiography and ventilation-perfusion scanning.

Initial Treatment Approach

Confirmed PE ↓ Hemodynamic Assessment ↓ Massive PE Submassive PE Low-risk PE (shock/hypotension) (RV dysfunction) (stable, no RV dysfunction) ↓ ↓ ↓ Thrombolysis Consider thrombolysis Anticoagulation

• Anticoagulation + Anticoagulation (outpatient possible) ↓ ↓ ↓ ICU monitoring Monitor closely Regular follow-up

Anticoagulation Therapy

First-line Agents (DOACs)

[HIGH_YIELD] Direct oral anticoagulants (DOACs) are preferred over warfarin for most patients due to predictable pharmacokinetics and no need for monitoring.

Parenteral Anticoagulation

Used when DOACs contraindicated or in massive PE:

• Unfractionated heparin: IV bolus 80 units/kg, then 18 units/kg/hr (monitor aPTT)
• Low molecular weight heparin: Enoxaparin 1 mg/kg SC BID
• Fondaparinux: 5-10 mg SC daily (based on weight)

Warfarin Therapy

• Indication: DOAC contraindicated, mechanical heart valves, severe renal disease
• Dosing: Start 5-10 mg daily, target INR 2.0-3.0
• Bridging: Overlap with parenteral anticoagulant until INR ≥2.0 for 24 hours

[CLINICAL_PEARL] Rivaroxaban and apixaban can be started immediately without heparin bridging, simplifying outpatient management.

Treatment Duration

Standard Recommendations

• Provoked PE: 3 months minimum
• First unprovoked PE: 3-6 months, consider indefinite
• Recurrent unprovoked PE: Indefinite anticoagulation
• Active cancer: 3-6 months, then reassess

Extended Anticoagulation Considerations

Factors favoring extended therapy:

• Unprovoked PE
• Recurrent VTE
• Active malignancy
• Antiphospholipid syndrome
• Low bleeding risk

Factors favoring limited therapy:

• Clear reversible risk factor
• High bleeding risk
• Patient preference

Special Populations

Cancer-Associated PE

• Preferred agents: LMWH (enoxaparin) or DOACs (apixaban, rivaroxaban)
• Duration: Minimum 3-6 months, often indefinite while cancer active
• Monitoring: Regular reassessment for bleeding and recurrence

Pregnancy

• Treatment: LMWH throughout pregnancy (DOACs contraindicated)
• Postpartum: Continue anticoagulation for 6 weeks postpartum (minimum 3 months total)
• Warfarin: Safe during breastfeeding

Renal Impairment

• CrCl >30 mL/min: Standard DOAC dosing with possible reduction
• CrCl 15-30 mL/min: Reduce DOAC dose or use warfarin
• CrCl <15 mL/min: Warfarin preferred (INR 2.0-3.0)

[KEY_CONCEPT] Bleeding risk assessment using tools like HAS-BLED score should be performed before starting anticoagulation, but bleeding risk rarely outweighs benefit in acute PE.

Monitoring and Follow-up

• DOAC therapy: No routine monitoring required
• Warfarin therapy: INR monitoring (weekly initially, then monthly when stable)
• Clinical follow-up: 1-2 weeks after diagnosis, then every 3 months
• Long-term complications: Screen for CTEPH if persistent symptoms at 6 months

Thrombolytic Therapy

[HIGH_YIELD] Systemic thrombolysis is indicated for massive PE and selected cases of submassive PE with evidence of clinical deterioration.

Indications for Thrombolysis

Absolute indications:

• Massive PE with hemodynamic instability
• Cardiac arrest due to PE

Relative indications (submassive PE):

• RV dysfunction + elevated troponin
• Clinical deterioration despite anticoagulation
• Massive clot burden on imaging

Thrombolytic Protocols

Contraindications to Thrombolysis

Absolute contraindications:

• Active internal bleeding
• Recent intracranial hemorrhage (<3 months)
• Known intracranial neoplasm or AVM
• Ischemic stroke within 3 months

Relative contraindications:

• Major surgery within 2 weeks
• Uncontrolled hypertension (>180/110 mmHg)
• Pregnancy
• Age >75 years

[CLINICAL_PEARL] Catheter-directed thrombolysis may be considered for submassive PE when systemic thrombolysis is contraindicated, offering localized therapy with potentially lower bleeding risk.

Mechanical Interventions

Surgical Embolectomy

• Indication: Massive PE with absolute contraindication to thrombolysis
• Mortality: 20-30% in experienced centers
• Approach: Median sternotomy with cardiopulmonary bypass

Catheter-Based Interventions

• Catheter embolectomy: Mechanical clot removal via catheter
• Ultrasound-assisted thrombolysis: Enhanced clot penetration
• Aspiration thrombectomy: Direct suction removal of clots

IVC Filter Placement

Indications for IVC Filters

Absolute indications:

• Acute VTE with absolute contraindication to anticoagulation
• Recurrent VTE despite adequate anticoagulation

Relative indications:

• Free-floating iliofemoral thrombus
• Chronic PE with severe pulmonary hypertension
• Prophylaxis in high-risk trauma patients

[KEY_CONCEPT] IVC filters should be retrievable when possible and removed once anticoagulation can be safely resumed to prevent long-term complications.

Complications of PE Treatment

Bleeding Complications

Major bleeding rates:

• DOACs: 1-3% annually
• Warfarin: 2-4% annually
• Thrombolysis: 5-10% major bleeding, 1-2% intracranial hemorrhage

Management of Anticoagulant-Related Bleeding

Bleeding Assessment ↓ Major Bleeding Minor Bleeding ↓ ↓ Stop anticoagulant Consider holding dose Reversal agent Monitor closely Supportive care Resume when safe

Reversal Agents

• DOAC reversal: Idarucizumab (dabigatran), andexanet alfa (rivaroxaban/apixaban)
• Warfarin reversal: Vitamin K + 4-factor PCC or FFP
• Heparin reversal: Protamine sulfate

Long-term Complications

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

• Incidence: 2-4% of PE survivors at 2 years
• Presentation: Progressive dyspnea, exercise limitation
• Diagnosis: Echocardiography, V/Q scan, right heart catheterization
• Treatment: Pulmonary endarterectomy, balloon pulmonary angioplasty, targeted therapy

Post-PE Syndrome

• Incidence: 50% of PE survivors
• Symptoms: Persistent dyspnea, exercise intolerance, chest pain
• Mechanism: Microvascular dysfunction, psychological factors
• Management: Pulmonary rehabilitation, exercise training, psychological support

[CLINICAL_PEARL] All PE patients should be educated about signs and symptoms of recurrent VTE and bleeding complications, with clear instructions on when to seek medical attention.